These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10907630)

  • 21. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T
    Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
    Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
    J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raloxifene. Not better than estrogen.
    Can Fam Physician; 2000 Aug; 46():1592-6, 1599-603. PubMed ID: 10955178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raloxifene therapy in the reduction of fractures.
    Cefalu CA
    Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
    [No Abstract]   [Full Text] [Related]  

  • 25. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
    Inaba M
    Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raloxifene and risk of vertebral fracture in postmenopausal women.
    Halbekath J; Becker-Brüser W; Wille H
    JAMA; 2000 May; 283(17):2236-7. PubMed ID: 10807376
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drugs in development for the treatment of osteoporosis:Raloxifene].
    Taga M
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():572-80. PubMed ID: 11979956
    [No Abstract]   [Full Text] [Related]  

  • 29. [Raloxifene hydrochloride].
    Itabashi A
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
    [No Abstract]   [Full Text] [Related]  

  • 30. Raloxifene reduces fractures in postmenopausal women with osteoporosis.
    Reginster JY; Devogelaer JP
    Clin Orthop Relat Res; 2006 Feb; 443():48-54. PubMed ID: 16462425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
    Kastelan D; Korsić M
    Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
    Legrand E; Hoppé E; Chappard D; Audran M
    Gynecol Obstet Fertil; 2006 May; 34(5):423-8. PubMed ID: 16697240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
    MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093
    [No Abstract]   [Full Text] [Related]  

  • 34. Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures?
    Rosenfeld JA
    West J Med; 2000 Sep; 173(3):186-8. PubMed ID: 10986186
    [No Abstract]   [Full Text] [Related]  

  • 35. Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
    Thiebaud D
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S124-5. PubMed ID: 21213508
    [No Abstract]   [Full Text] [Related]  

  • 36. Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
    Prescrire Int; 2000 Dec; 9(50):190-1. PubMed ID: 11475503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hormone replacement Up-to-date. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis].
    Hosoi T
    Clin Calcium; 2007 Sep; 17(9):1419-23. PubMed ID: 17767033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
    Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
    Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The science of selective estrogen receptor modulators: concept to clinical practice.
    Jordan VC
    Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.